Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Resverlogix Corp.

Market Cap 21.83M 15.41M 13.47M 12.46M 11.63M 1.46B 21.99M 148M 57.6M 716M 57.87M 56.61M 2.49B P/E 2024
-1.38x
P/E 2025 -2.68x
Enterprise Value 108M 75.99M 66.4M 61.42M 57.33M 7.18B 108M 730M 284M 3.53B 285M 279M 12.27B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
60.39%
Yield 2024 *
-
Yield 2025 -
1 day+5.56%
3 months-17.39%
6 months-5.00%
Current year-5.00%
1 week 0.09
Extreme 0.09
0.1
1 month 0.08
Extreme 0.085
0.1
Current year 0.08
Extreme 0.085
0.14
1 year 0.04
Extreme 0.035
0.3
3 years 0.04
Extreme 0.035
0.3
5 years 0.04
Extreme 0.035
0.9
10 years 0.04
Extreme 0.035
4.94
Manager TitleAgeSince
Chief Executive Officer - 2003-04-24
Director of Finance/CFO 78 2009-10-28
Chief Tech/Sci/R&D Officer - 2022-08-14
Director TitleAgeSince
Chairman - 2016-04-03
Director/Board Member 56 2009-10-14
Director/Board Member 66 2010-09-28
Date Insider Type Main position Quantity % Market Cap.
May. 03Option

Chief Financial Officer

300,000 0.0949%
May. 03Option

Chief Financial Officer

300,000 0.0949%
Mar. 05Option

Chief Financial Officer

250,000 0.0869%
Change 5-day change 1-year change 3-year change Capi.($)
+5.56%0.00%+137.50%-5.00% 21.83M
+2.87%+4.57%+70.82%+119.22% 55.19B
+4.00%+7.14%+63.67%+68.77% 45.75B
+0.46%+0.65%-11.28%-14.84% 22.98B
+3.31%+1.25%-6.39%+385.15% 20.76B
-0.26%-1.09%+27.55%-18.57% 16.26B
+1.16%+3.86%+22.36%-36.42% 15.42B
-0.95%-2.21%+19.51%+160.71% 13.05B
+3.30%+15.38%+133.24%+273.89% 12.45B
-5.63%-5.49%+21.79% - 12.37B
Average +1.38%+2.83%+47.88%+103.66% 21.43B
Weighted average by Cap. +1.84%+2.66%+43.91%+109.10%

Financials

2024 2025
Net sales - -
Net income -7.64M -5.39M -4.71M -4.36M -4.07M -509M -7.69M -51.78M -20.15M -250M -20.24M -19.8M -870M -7.77M -5.48M -4.79M -4.43M -4.14M -518M -7.82M -52.67M -20.5M -255M -20.59M -20.14M -885M
Net Debt 81.87M 57.81M 50.51M 46.72M 43.61M 5.46B 82.47M 555M 216M 2.69B 217M 212M 9.33B 85.79M 60.58M 52.93M 48.96M 45.7M 5.72B 86.42M 582M 226M 2.81B 227M 223M 9.78B
Logo Resverlogix Corp.
Resverlogix Corp. is a Canada-based late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. The Company focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The Company's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. It partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Employees
-
Date Price Change Volume
26-06-22 0.0950 $ +5.56% 2,100
26-06-19 0.0900 $ -10.00% 11,500
26-06-18 0.1000 $ 0.00% 4,000
26-06-17 0.1000 $ +5.26% 39,000
26-06-16 0.0950 $ 0.00% 65,052
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!